Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

Kiora Pharmaceuticals (KPRX) Debt to Equity (2020 - 2023)

Kiora Pharmaceuticals' Debt to Equity history spans 5 years, with the latest figure at $0.06 for Q3 2023.

  • For Q3 2023, Debt to Equity rose 104.86% year-over-year to $0.06; the TTM value through Sep 2023 reached $0.06, up 104.86%, while the annual FY2020 figure was $0.03, N/A changed from the prior year.
  • Debt to Equity reached $0.06 in Q3 2023 per KPRX's latest filing, up from $0.02 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.06 in Q3 2023 to a low of $0.02 in Q1 2021.
  • Average Debt to Equity over 4 years is $0.03, with a median of $0.03 recorded in 2022.
  • The largest YoY upside for Debt to Equity was 104.86% in 2023 against a maximum downside of 33.21% in 2023.
  • A 4-year view of Debt to Equity shows it stood at $0.03 in 2020, then crashed by 39.13% to $0.02 in 2021, then skyrocketed by 71.33% to $0.03 in 2022, then soared by 104.86% to $0.06 in 2023.
  • Per Business Quant, the three most recent readings for KPRX's Debt to Equity are $0.06 (Q3 2023), $0.02 (Q2 2023), and $0.03 (Q1 2023).